GAPDHP37

Across TCGA pan-cancer cohorts, GAPDHP37 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of GAPDHP37’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where GAPDHP37 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GAPDHP37 is over-expressed in tumor, although a few such as CHOL show the opposite, repressed pattern.

KIRC, COAD, and LIHC are the cancer types where GAPDHP37 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GAPDHP37 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	+0.132	<.001	7	view →
COAD	All	All	+0.164	<.001	6	view →
LIHC	All	All	+0.160	.001	3	view →
PAAD	Male	All	+0.130	.022	2	view →
CHOL	All	All	−0.116	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

GAPDHP37–KIRC

Open the KIRC breakdown →